Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

Ruilope, 2010 - LCZ696 vs

KYOTO HEART Study, 2009 - valsartan vs non ARB strategy

Schmieder (vs HCTZ), 2009 - aliskiren vs hydrochlorothiazide

ALLAY, 2009 - aliskiren vs losartan

AVOID, 2008 - aliskiren vs placebo

HYVET, 2008 - indapamide vs placebo

ACCOMPLISH, 2008 - amlodipine plus benazepril vs hydrochlorothiazide plus benazepril

Andersen, 2008 - aliskiren vs ramipril

PROPHESS, 2008 - telmisartan vs placebo

ASCOT-BPLA, 2005 - amlodipine vs atenolol

ASCOT-BPLA, 2005 - atenolol vs amlodipine

VALUE, 2004 - valsartan vs amlodipine

INVEST, 2003 - atenolol vs verapamil

CONVINCE, 2003 - verapamil vs diuretic or beta-blocker

SHELL, 2003 - lacidipine vs chlorthalidone

ANBP2, 2003 - enalapril vs diuretics

CONVINCE, 2003 - Atenolol or hydrochlorothiazide vs verapamil

SCOPE, 2003 - candesartan vs placebo

INVEST (Pepine), 2003 - verapamil vs atenolol

AASK (vs metoprolol), 2002 - ramipril vs metoprolol

AASK (vs metoprolol), 2002 - amlodipine vs metoprolol

ALLHAT (CCB vs ACEI), 2002 - amlodipine vs lisinopril

AASK (vs amlodipine), 2002 - ramipril vs amlodipine

ELSA, 2002 - atenolol vs lacidipine

LIFE, 2002 - losartan vs atenolol



See also:

  • All hypertension clinical trials
  • All clinical trials of renin inhibitor
  • All clinical trials of aliskiren
    		•  

    Andersen study, 2008

    Treatments

    Studied treatment aliskiren 150 mg (up to 300mg) daily
    Control treatment ramipril 5 mg (up to 10mg) daily
    Remarks Dose titration (to aliskiren 300 mg/ramipril 10 mg) and subsequent hydrochlorothiazide addition (12.5 mg, titrated to 25 mg if required) were permitted at weeks 6, 12, 18 and 21 for inadequate blood pressure control

    Patients

    Method and design

    Randomized effectives NA / NA (studied vs. control)
    Design Parallel groups
    Blinding double blind
    Follow-up duration 26 weeks
    Primary endpoint BP change


    Results

    No results available for this trial - no clinical endpoint reported



    Reference(s)

    Trials register # NA
    • Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.. J Hypertens 2008;26:589-99
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend